JP2013527243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527243A5 JP2013527243A5 JP2013513340A JP2013513340A JP2013527243A5 JP 2013527243 A5 JP2013527243 A5 JP 2013527243A5 JP 2013513340 A JP2013513340 A JP 2013513340A JP 2013513340 A JP2013513340 A JP 2013513340A JP 2013527243 A5 JP2013527243 A5 JP 2013527243A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 0 CC(C)([C@]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@](CC1)[C@]2(C)[C@](C)(CC2)[C@]1[C@@]([C@@](CC1)C(C)=C)[C@@]21*=O Chemical compound CC(C)([C@]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@](CC1)[C@]2(C)[C@](C)(CC2)[C@]1[C@@]([C@@](CC1)C(C)=C)[C@@]21*=O 0.000 description 3
- IYXWIGIBQRBZEA-SOPZNGSOSA-N CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCC(O)=O)=O Chemical compound CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCC(O)=O)=O IYXWIGIBQRBZEA-SOPZNGSOSA-N 0.000 description 2
- ICCXRMCAZXIEKB-DLOZVDQESA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(N(CCC1)C1C(O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(N(CCC1)C1C(O)=O)=O ICCXRMCAZXIEKB-DLOZVDQESA-N 0.000 description 1
- PNYXMECLMCGFQO-IVTMKUIASA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NC1(CC1)c1ncccc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NC1(CC1)c1ncccc1)=O PNYXMECLMCGFQO-IVTMKUIASA-N 0.000 description 1
- GISHHOXBHMHXAT-LXMJURFTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCN(C)CCOC(CCC(O)=O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCN(C)CCOC(CCC(O)=O)=O)=O GISHHOXBHMHXAT-LXMJURFTSA-N 0.000 description 1
- DJDFBYUCRSCJOY-YDDYIPHKSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCN)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCN)=O DJDFBYUCRSCJOY-YDDYIPHKSA-N 0.000 description 1
- HOEUXIFGSWBPRD-MLQCUHPCSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCNc(cc1)ccc1C(O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCNc(cc1)ccc1C(O)=O)=O HOEUXIFGSWBPRD-MLQCUHPCSA-N 0.000 description 1
- NIIANVHGHGAQHR-PIHDDTHSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCc(cc1)ccc1OC)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCc(cc1)ccc1OC)=O NIIANVHGHGAQHR-PIHDDTHSSA-N 0.000 description 1
- JCAHWJXOEGWXMM-RPAAZHKCSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCc1cccnc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCCc1cccnc1)=O JCAHWJXOEGWXMM-RPAAZHKCSA-N 0.000 description 1
- FKZMLTXZYUTDEJ-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1c[o]cc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1c[o]cc1)=O FKZMLTXZYUTDEJ-WECSNRJHSA-N 0.000 description 1
- JHFVLSGGKCWBBT-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1ccc[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1ccc[s]1)=O JHFVLSGGKCWBBT-WECSNRJHSA-N 0.000 description 1
- VWFKFNBWBFXWHB-MTDMPAKNSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1nc(cccc2)c2[nH]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1nc(cccc2)c2[nH]1)=O VWFKFNBWBFXWHB-MTDMPAKNSA-N 0.000 description 1
- BKAYPESJABYHRZ-NFEAHYNFSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1ncc[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(NCc1ncc[s]1)=O BKAYPESJABYHRZ-NFEAHYNFSA-N 0.000 description 1
- ZTLKAKJRMUYOQJ-ZNXZYOFTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1nc(C(O)=O)c(C)[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1nc(C(O)=O)c(C)[s]1)=O ZTLKAKJRMUYOQJ-ZNXZYOFTSA-N 0.000 description 1
- ZBAMSHSTLVXZLA-FGTRPOGWSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1ncc(C(O)=O)[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1ncc(C(O)=O)[s]1)=O ZBAMSHSTLVXZLA-FGTRPOGWSA-N 0.000 description 1
- PATBAKZXMYHORB-KXVYAZENSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1ncc(C)[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1ncc(C)[s]1)=O PATBAKZXMYHORB-KXVYAZENSA-N 0.000 description 1
- HBQNBVRDYIMTRX-LWVALZDHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1nnc[s]1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21C(Nc1nnc[s]1)=O HBQNBVRDYIMTRX-LWVALZDHSA-N 0.000 description 1
- RBKAZZIJGKVWQX-ZHOFKQHZSA-N CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCN(C)C)=O Chemical compound CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCN(C)C)=O RBKAZZIJGKVWQX-ZHOFKQHZSA-N 0.000 description 1
- REUSEPFORFXNQD-AXODBVIISA-N CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCc1ccccn1)=O Chemical compound CC(C)[C@H](CC1)[C@H]([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)[C@H]2[C@@](C)(CC2)[C@@H]4C(C)(C)[C@H]2c(cc2)ccc2C(O)=O)[C@]13C(NCCc1ccccn1)=O REUSEPFORFXNQD-AXODBVIISA-N 0.000 description 1
- DNQNHJSTDGTCIR-IWISFVJQSA-N CCN1C(CNC([C@@](CC[C@H]2C(C)=C)(CC3)[C@H]2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)[C@H]2[C@]2(C)[C@@H]3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)=O)CCC1 Chemical compound CCN1C(CNC([C@@](CC[C@H]2C(C)=C)(CC3)[C@H]2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)[C@H]2[C@]2(C)[C@@H]3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)=O)CCC1 DNQNHJSTDGTCIR-IWISFVJQSA-N 0.000 description 1
- DGMMBLTVYFUCLD-UHFFFAOYSA-N NCCC(N(CC1)CCC1C(O)=O)=O Chemical compound NCCC(N(CC1)CCC1C(O)=O)=O DGMMBLTVYFUCLD-UHFFFAOYSA-N 0.000 description 1
- FZWUTBBNGPSHBP-UHFFFAOYSA-N NCCC(N(CCC1)C1C(O)=O)=O Chemical compound NCCC(N(CCC1)C1C(O)=O)=O FZWUTBBNGPSHBP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35133210P | 2010-06-04 | 2010-06-04 | |
| US61/351,332 | 2010-06-04 | ||
| PCT/US2011/038884 WO2011153319A1 (en) | 2010-06-04 | 2011-06-02 | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527243A JP2013527243A (ja) | 2013-06-27 |
| JP2013527243A5 true JP2013527243A5 (enExample) | 2014-07-17 |
| JP5755731B2 JP5755731B2 (ja) | 2015-07-29 |
Family
ID=44627254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513340A Expired - Fee Related JP5755731B2 (ja) | 2010-06-04 | 2011-06-02 | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8802661B2 (enExample) |
| EP (1) | EP2576586B1 (enExample) |
| JP (1) | JP5755731B2 (enExample) |
| CN (1) | CN102985438B (enExample) |
| AR (1) | AR081638A1 (enExample) |
| BR (1) | BR112012030810A2 (enExample) |
| CA (1) | CA2801491C (enExample) |
| DK (1) | DK2576586T3 (enExample) |
| EA (1) | EA026140B1 (enExample) |
| ES (1) | ES2548905T3 (enExample) |
| HR (1) | HRP20150977T1 (enExample) |
| HU (1) | HUE026662T2 (enExample) |
| MX (1) | MX2012013628A (enExample) |
| PL (1) | PL2576586T3 (enExample) |
| PT (1) | PT2576586E (enExample) |
| RS (1) | RS54239B1 (enExample) |
| SI (1) | SI2576586T1 (enExample) |
| SM (1) | SMT201500272B (enExample) |
| TW (1) | TW201201792A (enExample) |
| WO (1) | WO2011153319A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2670764T1 (sl) * | 2011-01-31 | 2016-03-31 | Bristol-Myers Squibb Company | C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv |
| CA2826113C (en) * | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| MX2014002936A (es) | 2011-09-21 | 2014-04-25 | Bristol Myers Squibb Co | Nuevos derivados de acido betulinico con actividad antiviral. |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| WO2014105926A1 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Novel betulinic acid proline derivatives as hiv inhibitors |
| US20140221361A1 (en) * | 2013-02-06 | 2014-08-07 | Bristol-Myers Squibb Company | C-19 modified triterpenoids with hiv maturation inhibitory activity |
| CN105102468A (zh) * | 2013-02-25 | 2015-11-25 | 百时美施贵宝公司 | 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物 |
| PL3129392T3 (pl) | 2014-04-11 | 2021-04-06 | VIIV Healthcare UK(No.4) Limited | Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy |
| WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
| WO2015198263A2 (en) * | 2014-06-26 | 2015-12-30 | Hetero Research Foundation | Novel betulinic proline substituted derivatives as hiv inhibitors |
| US20170129916A1 (en) | 2014-06-26 | 2017-05-11 | Hetero Research Foundation | Novel betulinic proline imidazole derivatives as hiv inhibitors |
| BR112017009850A2 (pt) * | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto |
| KR20170092581A (ko) | 2014-11-14 | 2017-08-11 | 비브 헬스케어 유케이 (넘버5) 리미티드 | Ｃ１７-아릴 치환된 베툴린산 유사체 |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| US10370405B2 (en) | 2015-03-16 | 2019-08-06 | Hetero Labs Limited | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors |
| EP3328876A1 (en) | 2015-07-28 | 2018-06-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Betuin derivatives for preventing or treating hiv infections |
| KR20180028535A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| AU2016327169A1 (en) | 2015-09-24 | 2018-04-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds with hiv maturation inhibitory activity |
| JP2019502728A (ja) | 2016-01-20 | 2019-01-31 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ成熟阻害活性を有するルパンのアミン誘導体 |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| US20190135857A1 (en) * | 2016-06-30 | 2019-05-09 | Viiv Healthcare Uk (No. 5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| EP3784349B1 (en) | 2018-04-24 | 2023-12-27 | VIIV Healthcare UK (No.5) Limited | Compounds with hiv maturation inhibitory activity |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| US10343997B1 (en) | 2018-12-04 | 2019-07-09 | King Saud University | Ursolic acid derivatives |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| ES2281960T3 (es) * | 1998-03-02 | 2007-10-01 | The University Of North Carolina At Chapel Hill | Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso. |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| NZ538896A (en) * | 2002-09-26 | 2007-10-26 | Niigata University Of Pharmacy | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| AU2005224260A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| US20060019934A1 (en) * | 2004-05-20 | 2006-01-26 | Saxena Brij B | Anti-HIV-1 activity of betulinol derivatives |
| US7282521B2 (en) | 2004-05-24 | 2007-10-16 | University Of North Carolina At Chapel Hill | Anti-retroviral moronic acid derivatives |
| TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| EP1986654A2 (en) * | 2006-02-21 | 2008-11-05 | Achillion Pharmaceuticals, Inc. | Substituted taraxastanes useful for treating viral infections |
| WO2008097341A2 (en) | 2006-07-26 | 2008-08-14 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) * | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| WO2009020732A1 (en) * | 2007-08-03 | 2009-02-12 | Advanced Life Sciences, Inc. | Lupane-type triterpenoids modified at 30-position and analogues thereof |
| WO2009042166A1 (en) | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| WO2009114083A2 (en) | 2008-03-03 | 2009-09-17 | Panacos Pharmaceuticals, Inc. | Determinants of antiviral response |
| WO2009129548A1 (en) * | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| US20120302534A1 (en) * | 2010-02-11 | 2012-11-29 | Daxin Gao | Derivatives of betulin |
-
2011
- 2011-06-02 ES ES11726564.5T patent/ES2548905T3/es active Active
- 2011-06-02 CA CA2801491A patent/CA2801491C/en not_active Expired - Fee Related
- 2011-06-02 SI SI201130604T patent/SI2576586T1/sl unknown
- 2011-06-02 EP EP11726564.5A patent/EP2576586B1/en active Active
- 2011-06-02 MX MX2012013628A patent/MX2012013628A/es active IP Right Grant
- 2011-06-02 US US13/151,722 patent/US8802661B2/en not_active Expired - Fee Related
- 2011-06-02 HR HRP20150977TT patent/HRP20150977T1/hr unknown
- 2011-06-02 HU HUE11726564A patent/HUE026662T2/en unknown
- 2011-06-02 CN CN201180035812.4A patent/CN102985438B/zh not_active Expired - Fee Related
- 2011-06-02 PT PT117265645T patent/PT2576586E/pt unknown
- 2011-06-02 WO PCT/US2011/038884 patent/WO2011153319A1/en not_active Ceased
- 2011-06-02 EA EA201270800A patent/EA026140B1/ru not_active IP Right Cessation
- 2011-06-02 JP JP2013513340A patent/JP5755731B2/ja not_active Expired - Fee Related
- 2011-06-02 BR BR112012030810A patent/BR112012030810A2/pt not_active IP Right Cessation
- 2011-06-02 DK DK11726564.5T patent/DK2576586T3/en active
- 2011-06-02 RS RS20150587A patent/RS54239B1/sr unknown
- 2011-06-02 PL PL11726564T patent/PL2576586T3/pl unknown
- 2011-06-03 AR ARP110101945A patent/AR081638A1/es not_active Application Discontinuation
- 2011-06-03 TW TW100119710A patent/TW201201792A/zh unknown
-
2015
- 2015-10-30 SM SM201500272T patent/SMT201500272B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527243A5 (enExample) | ||
| JP2013527242A5 (enExample) | ||
| JP2014507422A5 (enExample) | ||
| JP2014503595A5 (enExample) | ||
| JP2015510515A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2013510124A5 (enExample) | ||
| JP2014526554A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| JP2012524055A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| HRP20150977T1 (hr) | C-28 amidi modificiranih derivata c-3 betulinske kiseline kao inhibitori sazrijevanja hiv-a | |
| JP2013518832A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| ECSP13012812A (es) | Formulaciones inmunosupresoras | |
| JP2017531038A5 (enExample) | ||
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| JP2012144574A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2016509062A5 (enExample) | ||
| JP2016510323A5 (enExample) | ||
| JP2016503052A5 (enExample) | ||
| JP2015516427A5 (enExample) |